AlphAIAlphAI — Financial news for AI agents
tradingview.comAUG 141 min read$BAP

Credicorp Ltd. Stock 12‑Month Price Target Raised to $437.02, Implies 16% Upside

Analysts covering Credicorp Ltd. raised the consensus 12-month price target to $437.02 from $433.39, based on 13 estimates. Targets range from $376.15 to $480.13. Using the Aug. 13 closing price, the update implies about 16% upside. The consensus rating remains “Buy” with 10 Buys, 3 Holds, and 0 Sells.

Original reporting
tradingview.com
Published Aug 14, 2026, 7:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 8:17 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Credicorp Ltd. Stock 12‑Month Price Target Raised to $437.02, Implies 16% Upside — source image
Source · tradingview.com
Decision brief

The 30-second read

$BAPBullishLow
01

Why it matters

A higher consensus PT and unchanged “Buy” rating can reinforce bullish positioning, but the lack of new company-specific information limits trading edge.

02

Market read

This is a sentiment/expectations update rather than a fundamental disclosure.

03

What to watch

The article does not provide the underlying thesis for the PT change, so traders should not assume improved fundamentals or revised earnings estimates.

Relevance 4/10Novelty 4/10Timing: pre-market today (published 07:20 UTC)

Background

The piece summarizes FactSet-based analyst consensus: average 12-month PT, range, and rating distribution.

Company-level read

Ticker impact

$BAPBullishMedium confidence
Context

Credicorp’s average analyst price target rose from $433.39 to $437.02, implying about 16% upside versus the Aug. 13 close.

Expected impact

Mild positive bias for the stock over days, with limited follow-through unless new company-specific fundamentals emerge.

Evidence & confidence

The article reports a consensus price-target revision and unchanged rating mix, without any new earnings, guidance, or operational disclosure.

Market effects

Sector

Limited sector read-through because the update is purely analyst PT consensus, not a sector-wide fundamental change.

Regional

Minimal, as the note does not cite Peru/LatAm macro or regulatory developments.

Global

Low, since it is a single-company analyst target update without broader market catalysts.

Counterpoint

What could challenge this read

Price-target changes can lag fundamentals; without new earnings or guidance, the market may discount the PT update quickly.

Key entities

  • public_company
    Credicorp Ltd.

    Subject of the article, with analyst consensus 12-month price target raised to $437.02.

Read at source← All news

Related articles

AUG 14
$BAPMedAI 8/10

Credicorp Q2 Earnings Call Highlights

Credicorp (NYSE:BAP) discussed Q2 results and outlook on an earnings call, including plans to reassess El Niño-related expected losses by late Q3 or early Q4. Management said full-year 2026 cost of risk should stay within guidance, raised 2026 loan-growth to ~12% and fee-income to high-teens, and reaffirmed 2026 ROE guidance ~19.5%. BCP ROE 29.2%, Mibanco ROE 22.9%, Yape has 16M+ MAUs.

yahoo.com4 min
MAY 26
$BAPHighAI 9/10

Bapcor Shares Upgraded, As Price Target Slashed: Value or Trap?

Jefferies upgraded Bapcor (ASX: BAP) to Buy from Hold but cut its price target from A$1.05 to A$0.65. The stock has fallen about 75% over six months and is near A$0.38. Bapcor also secured temporary relief on its net leverage covenant, raising it to 3.5x adjusted EBITDA for test dates through 2026.

thebull.com.au6 min
OCT 28
$FWRDMed

Forward Air Announces Two-Year Definitive Agreement to Retain Significant Portion of Previously Disclosed Customer Relationship

FORWARD AIR CORP (FWRD) filed an SEC Form 8-K — Other Events. Forward Air Announces Two-Year Definitive Agreement to Retain Significant Portion of Previously Disclosed Customer Relationship 2026 to 2028 Forecasted Annual Revenue from Customer Expected to Exceed 2025 Revenue Driven by Growth in Retained Services DALLAS – October 28, 2026 – F

SEC EDGAR 8-K4 min
OCT 28
$PYPDMedAI 8/10

PolyPid unveils PD01B for diabetic foot infection treatment

PolyPid Ltd. (NASDAQ:PYPD) introduced PD01B, a product candidate for treating moderate to severe diabetic foot infections, using its Kynatrix delivery technology. The company plans to initiate a first-in-human study in the second half of 2027. PolyPid also expects a decision on its lead product D-PLEX₁₀₀ by November 28, 2026, with a potential U.S. launch in early 2027, subject to FDA approval.

investing.com2 min
OCT 28
$KTOSMed

Kratos wins $33.6 million NASA power system contract

Kratos Defense & Security Solutions (KTOS) won a $33.6M contract from NASA to design and build a power system for the Space Reactor-1 Freedom spacecraft, launching in 2028. Kratos will work as a subcontractor to Sierra Lobo under NASA’s SpaceDOC III contract, providing a power conversion system for the mission to Mars. The spacecraft aims to demonstrate nuclear electric propulsion technology. According to the company, the contract is a significant milestone in advancing space nuclear propulsion.

investing.com3 min